RESUMO
Importance: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) may experience life-threatening arrhythmic events (LTAEs) despite ß-blocker treatment. Further complicating management, the role of implantable cardioverter defibrillator (ICD) in CPVT is debated. Objective: To investigate the long-term outcomes of patients with RYR2 CPVT treated with ß-blockers only and the cost to benefit ratio of ICD. Design, Settings, and Participants: This prospective cohort study conducted from January 1988 to October 2020 with a mean (SD) follow-up of 9.4 (7.5) years included patients who were referred to the Molecular Cardiology Clinics of ICS Maugeri Hospital, Pavia, Italy. Participants included consecutive patients with CPVT who were carriers of a pathogenic or likely pathogenic RYR2 variant with long-term clinical follow-up. Exposures: Treatment with selective and nonselective ß-blocker only and ICD implant when indicated. Main Outcome and Measures: The main outcome was the occurrence of the first LTAE while taking a ß-blocker. LTAE was defined as a composite of 3 hard end points: sudden cardiac death, aborted cardiac arrest, and hemodynamically nontolerated ventricular tachycardia. Results: The cohort included 216 patients with RYR2 CPVT (121 of 216 female [55%], median [IQR] age 14, [9-30] years). During a mean (SD) follow-up of 9.4 (7.5) years taking ß-blockers only, 28 of 216 patients (13%) experienced an LTAE (annual rate, 1.9%; 95% CI, 1.3-2.7). In multivariable analysis, experiencing either an LTAE (hazard ratio [HR], 3.3; 95% CI, 1.2-8.9; P = .02) or syncope before diagnosis (HR, 4.5; 95% CI, 1.8-11.1; P = .001) and carrying a C-terminal domain variant (HR, 18.1; 95% CI, 4.1-80.8; P < .001) were associated with an increased LTAE risk during ß-blocker therapy only. The risk of LTAE among those taking selective ß-blockers vs nadolol was increased 6-fold (HR, 5.8; 95% CI, 2.1-16.3; P = .001). Conversely, no significant difference was present between propranolol and nadolol (HR, 1.8; 95% CI, 0.4-7.3; P = .44). An ICD was implanted in 79 of 216 patients (37%) who were followed up for a mean (SD) of 8.6 (6.3) years. At the occurrence of LTAE, ICD carriers were more likely to survive (18 of 18 [100%]) than non-ICD carriers (6 of 10 [60%]; P = .01). Conclusions and Relevance: In this cohort study, selective ß-blockers were associated with a higher risk of LTAE as compared with nadolol. Independently from treatment, LTAE and syncope before diagnosis and C-terminal domain variants identified patients at higher risk of ß-blocker failure, and the ICD was associated with reduced mortality in high-risk patients with CPVT.
Assuntos
Nadolol , Taquicardia Ventricular , Adolescente , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Criança , Estudos de Coortes , Eletrocardiografia , Feminino , Humanos , Masculino , Nadolol/uso terapêutico , Estudos Prospectivos , Canal de Liberação de Cálcio do Receptor de Rianodina/genética , Síncope , Taquicardia Ventricular/diagnóstico , Adulto JovemRESUMO
BACKGROUND: Evidence for the role of the CACNA1C gene, which encodes for the α-subunit of the cardiac L-type calcium channel CaV1.2, as a cause of the BrS3 variant of Brugada syndrome (BrS) is contradictory. OBJECTIVE: The purpose of this study was to define in a large BrS cohort the yield of molecular screening and to test whether appropriate patient selection could improve clinical utility. METHODS: A total of 709 patients were included in this study. BrS probands (n = 563, consecutively referred) underwent CACNA1C sequencing. Two matched cohorts where defined: discovery cohort (n = 200) and confirmation cohort (n = 363). In addition, the clinical phenotypes of a matched SCN5A-positive BrS cohort (n = 146) were included for comparative genotype-phenotype correlation. RESULTS: In the discovery cohort, we identified 11 different rare variants in 9 patients; 10 of the variants (5%) were considered potentially causative based on their frequency in the general population. However, American College of Medical Genetics criteria were unable to classify the majority (80%) of them, which eventually were labeled as variants of unknown significance (VUS). Functional studies revealed a loss of function for 9 variants, pointing to a prevalence of CACNA1C causative variants in 4% of the discovery cohort. Genotype-phenotype correlation showed that pathogenic variants are significantly more frequent in patients with shorter QTc (12.9% vs 2.2% in patients with QTc <390 ms). CONCLUSION: CACNA1C is an infrequent but definitive cause of BrS typically associated with short QT. Functional studies are highly relevant to improve variant interpretation.
Assuntos
Síndrome de Brugada , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/epidemiologia , Síndrome de Brugada/genética , Canais de Cálcio Tipo L/genética , Testes Genéticos , Humanos , Mutação , Canal de Sódio Disparado por Voltagem NAV1.5/genética , Fenótipo , PrevalênciaAssuntos
Tratamento Farmacológico da COVID-19 , Hidroxicloroquina/farmacologia , Síndrome do QT Longo/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , COVID-19/epidemiologia , COVID-19/virologia , Eletrocardiografia/métodos , Feminino , Humanos , Síndrome do QT Longo/epidemiologia , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Andersen-Tawil Syndrome type 1 (ATS1) is a rare arrhythmogenic disorder, caused by loss-of-function mutations in the KCNJ2 gene. We present here the largest cohort of patients with ATS1 with outcome data reported. OBJECTIVES: This study sought to define the risk of life-threatening arrhythmic events (LAE), identify predictors of such events, and define the efficacy of antiarrhythmic therapy in patients with ATS1. METHODS: Clinical and genetic data from consecutive patients with ATS1 from 23 centers were entered in a database implemented at ICS Maugeri in Pavia, Italy, and pooled for analysis. RESULTS: We enrolled 118 patients with ATS1 from 57 families (age 23 ± 17 years at enrollment). Over a median follow-up of 6.2 years (interquartile range: 2.7 to 16.5 years), 17 patients experienced a first LAE, with a cumulative probability of 7.9% at 5 years. An increased risk of LAE was associated with a history of syncope (hazard ratio [HR]: 4.54; p = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with the administration of amiodarone (HR: 268; p < 0.001). The rate of LAE without therapy (1.24 per 100 person-years [py]) was not reduced by beta-blockers alone (1.37 per 100 py; p = 1.00), or in combination with Class Ic antiarrhythmic drugs (1.46 per 100 py, p = 1.00). CONCLUSIONS: Our data demonstrate that the clinical course of patients with ATS1 is characterized by a high rate of LAE. A history of unexplained syncope or of documented sustained ventricular tachycardia is associated with a higher risk of LAE. Amiodarone is proarrhythmic and should be avoided in patients with ATS1.
Assuntos
Síndrome de Andersen/complicações , Arritmias Cardíacas/etiologia , Medição de Risco , Adolescente , Antagonistas Adrenérgicos beta/uso terapêutico , Adulto , Amiodarona/administração & dosagem , Amiodarona/efeitos adversos , Síndrome de Andersen/genética , Síndrome de Andersen/terapia , Antiarrítmicos/administração & dosagem , Antiarrítmicos/efeitos adversos , Arritmias Cardíacas/terapia , Criança , Pré-Escolar , Bases de Dados Factuais , Morte Súbita Cardíaca/epidemiologia , Desfibriladores Implantáveis , Eletrocardiografia , Feminino , Testes Genéticos , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Mutação , Canais de Potássio Corretores do Fluxo de Internalização/genética , Síncope/etiologia , Síncope/terapia , Taquicardia Ventricular/etiologia , Taquicardia Ventricular/terapia , Adulto JovemAssuntos
Arritmias Cardíacas , Síndrome de Brugada , Parada Cardíaca , Administração dos Cuidados ao Paciente/métodos , Medição de Risco/métodos , Adolescente , Arritmias Cardíacas/etiologia , Arritmias Cardíacas/terapia , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/epidemiologia , Síndrome de Brugada/fisiopatologia , Síndrome de Brugada/terapia , Criança , Eletrocardiografia/métodos , Feminino , Seguimentos , Parada Cardíaca/diagnóstico , Parada Cardíaca/prevenção & controle , Humanos , Itália/epidemiologia , Masculino , Seleção de Pacientes , Fatores de Risco , Avaliação de Sintomas/métodos , Avaliação de Sintomas/estatística & dados numéricosRESUMO
BACKGROUND: Long QT syndrome (LQTS) is a common inheritable arrhythmogenic disorder, often secondary to mutations in the KCNQ1, KCNH2, and SCN5A genes. The disease is characterized by a prolonged ventricular repolarization (QTc interval) that confers susceptibility to life-threatening arrhythmic events (LAEs). OBJECTIVES: This study sought to create an evidence-based risk stratification scheme to personalize the quantification of the arrhythmic risk in patients with LQTS. METHODS: Data from 1,710 patients with LQTS followed up for a median of 7.1 years (interquartile range [IQR]: 2.7 to 13.4 years) were analyzed to estimate the 5-year risk of LAEs based on QTc duration and genotype and to assess the antiarrhythmic efficacy of beta-blockers. RESULTS: The relationship between QTc duration and risk of events was investigated by comparison of linear and cubic spline models, and the linear model provided the best fit. The 5-year risk of LAEs while patients were off therapy was then calculated in a multivariable Cox model with QTc and genotype considered as independent factors. The estimated risk of LAEs increased by 15% for every 10-ms increment of QTc duration for all genotypes. Intergenotype comparison showed that the risk for patients with LQT2 and LQT3 increased by 130% and 157% at any QTc duration versus patients with LQT1. Analysis of response to beta-blockers showed that only nadolol reduced the arrhythmic risk in all genotypes significantly compared with no therapy (hazard ratio: 0.38; 95% confidence interval: 0.15 to 0.93; p = 0.03). CONCLUSIONS: The study provides an estimator of risk of LAEs in LQTS that allows a granular estimate of 5-year arrhythmic risk and demonstrate the superiority of nadolol in reducing the risk of LAEs in LQTS.
Assuntos
Coração/fisiopatologia , Síndrome do QT Longo/fisiopatologia , Estudos de Coortes , Feminino , Genótipo , Humanos , Síndrome do QT Longo/genética , Masculino , Medição de RiscoRESUMO
BACKGROUND: Short QT syndrome (SQTS) is a rare and life-threatening arrhythmogenic syndrome characterized by abbreviated repolarization. Hydroquinidine (HQ) prolongs the QT interval in SQTS patients, although whether it reduces cardiac events is currently unknown. OBJECTIVES: This study investigated whether long-term treatment with HQ reduces the occurrence of life-threatening arrhythmic events (LAE) (cardiac arrest or sudden cardiac death) in SQTS patients. METHODS: In this cohort study on consecutive SQTS patients, 2 analyses were performed: 1) a matched-period analysis for the occurrence of LAE in 17 SQTS patients who received long-term HQ; and 2) a comparison of the annual incidence of LAE off- and on-HQ in 16 SQTS patients who survived a cardiac arrest. RESULTS: A total of 17 patients (82% male, age 29 ± 3 years, QTc before treatment 331 ± 3 ms) received HQ therapy (584 ± 53 mg/day). Therapy was stopped in 2 cases (12%) due to gastrointestinal intolerance, and 15 patients continued treatment for 6 ± 1 year. QTc prolongation was observed in all patients (by 60 ± 6 ms; p < 0.001). We compared the occurrence of LAE during 6 ± 1 years before and after HQ, observing that patients on HQ experienced a reduction in both the rate of LAE from 40% to 0% (p = 0.03) and the number of LAE per patient from 0.73 ± 0.3 to 0 (p = 0.026). Furthermore, the annual rate of LAE in the 16 patients with a previous cardiac arrest dropped from 12% before HQ to 0 on therapy (p = 0.028). CONCLUSIONS: We demonstrated for the first time that treatment with HQ was associated with a lower incidence of LAE in SQTS patients. These data point to the importance that quinidine, that in several countries has been removed from the market, remains available worldwide for patients with SQTS. In the present study, therapy with HQ has been proven to be safe, with a relatively low rate of side effects.
Assuntos
Arritmias Cardíacas/tratamento farmacológico , Morte Súbita Cardíaca/prevenção & controle , Quinidina/análogos & derivados , Fibrilação Ventricular/prevenção & controle , Adolescente , Adulto , Antiarrítmicos/administração & dosagem , Arritmias Cardíacas/complicações , Arritmias Cardíacas/fisiopatologia , Morte Súbita Cardíaca/epidemiologia , Morte Súbita Cardíaca/etiologia , Eletrocardiografia , Feminino , Seguimentos , Sistema de Condução Cardíaco/efeitos dos fármacos , Sistema de Condução Cardíaco/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Incidência , Itália/epidemiologia , Masculino , Quinidina/administração & dosagem , Taxa de Sobrevida/tendências , Fibrilação Ventricular/complicações , Fibrilação Ventricular/epidemiologia , Adulto JovemRESUMO
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a leading cause of sudden cardiac death, but its progression over time and predictors of arrhythmias are still being defined. OBJECTIVES: This study sought to describe the clinical course of ARVC and occurrence of life-threatening arrhythmic events (LAE) and cardiovascular mortality; identify risk factors associated with increased LAE risk; and define the response to therapy. METHODS: We determined the clinical course of 301 consecutive patients with ARVC using the Kaplan-Meier method adjusted to avoid the bias of delayed entry. Predictors of LAE over 5.8 years of follow-up were determined with Cox multivariable analysis. Treatment efficacy was assessed comparing LAE rates during matched time intervals. RESULTS: A first LAE occurred in 1.5 per 100 person-years between birth and age 20 years, in 4.0 per 100 person-years between ages 21 and 40 years, and in 2.4 per 100 person-years between ages 41 and 60 years. Cumulative probability of a first LAE at follow-up was 14% at 5 years, 23% at 10 years, and 30% at 15 years. Higher risk of LAE was predicted by atrial fibrillation (hazard ratio [HR]: 4.38; p = 0.002), syncope (HR: 3.36; p < 0.001), participation in strenuous exercise after the diagnosis (HR: 2.98; p = 0.028), hemodynamically tolerated sustained monomorphic ventricular tachycardia (HR: 2.19; p = 0.023), and male sex (HR: 2.49; p = 0.012). No difference was observed in the occurrence of LAE before and after treatment with amiodarone, beta-blockers, sotalol, or ablation. A total of 81 patients received an implantable cardioverter-defibrillator, 34 were successfully defibrillated. CONCLUSIONS: The high risk of life-threatening arrhythmias in patients with ARVC spans from adolescence to advanced age, reaching its peak between ages 21 and 40 years. Atrial fibrillation, syncope, participation in strenuous exercise after the diagnosis of ARVC, hemodynamically tolerated sustained monomorphic ventricular tachycardia, and male sex predicted lethal arrhythmias at follow-up. The lack of efficacy of antiarrhythmic therapy and the life-saving role of the implantable cardioverter-defibrillator highlight the importance of risk stratification for patient management.
Assuntos
Displasia Arritmogênica Ventricular Direita/diagnóstico , Morte Súbita Cardíaca/etiologia , Medição de Risco/métodos , Adolescente , Adulto , Displasia Arritmogênica Ventricular Direita/complicações , Displasia Arritmogênica Ventricular Direita/epidemiologia , Criança , Pré-Escolar , Morte Súbita Cardíaca/epidemiologia , Morte Súbita Cardíaca/prevenção & controle , Desfibriladores Implantáveis , Progressão da Doença , Feminino , Seguimentos , Humanos , Incidência , Lactente , Recém-Nascido , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Taxa de Sobrevida/tendências , Fatores de Tempo , Adulto JovemRESUMO
INTRODUCTION: The 2013 HRS/EHRA/APHRS consensus statement recommends the use of V1 and V2 leads recorded in the second and third intercostal spaces (High-ICS) for diagnosis of Brugada syndrome (BrS) creating a new category of patients discovered only with modified leads. The clinical presentation and the arrhythmic risk in these patients are ill defined. This study was aimed at assessing the role of High-ICS in the analysis of BrS and the clinical profile of the patients diagnosed only when ECG leads are moved to upper intercostal spaces. METHODS AND RESULTS: We searched our Brugada syndrome registry and identified 300 subjects (age 36 ± 13 years), without a diagnostic coved ST-segment elevation in conventional V1 -V3 leads, both at baseline and after provocative drug challenge. Sixty-four subjects (21.3%, mean age at last follow-up 42 ± 11 years) were diagnosed with High-ICS. Diagnosis was possible at baseline only in 4 subjects while in 60 it was made after drug challenge with sodium channel blockers. Three subjects (4.7%) with spontaneous abnormal ECG experienced cardiac events with an annual event rate (0.11%) superimposable to that of the low risk category of BrS diagnosed in standard leads. CONCLUSION: This study demonstrates that the use of new diagnostic criteria for BrS allows increasing the diagnostic yield by 20% and that the arrhythmic risk is low when BrS can be established only in High-ICS. We also show that the prognostic value of spontaneous ECG pattern is confirmed in this subgroup.
Assuntos
Síndrome de Brugada/diagnóstico , Eletrocardiografia , Sistema de Condução Cardíaco/fisiopatologia , Potenciais de Ação , Adulto , Síndrome de Brugada/fisiopatologia , Síndrome de Brugada/terapia , Eletrocardiografia/normas , Feminino , Frequência Cardíaca , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Valor Preditivo dos Testes , Prognóstico , Sistema de Registros , Adulto JovemRESUMO
BACKGROUND: Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-function mutations in the SCN5A gene, coding for the alpha-subunit of the sodium channel NaV1.5. Mexiletine is used to block late sodium current and to shorten QT interval in LQT3 patients. OBJECTIVES: The aim of this study was to determine whether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients. METHODS: The endpoint of this retrospective cohort study, which studied consecutive LQT3 patients who were referred to our center and treated with mexiletine, was to evaluate the antiarrhythmic efficacy of mexiletine by comparing the number of arrhythmic events per patient and the annual rate of arrhythmic events during observation periods of equal duration before and after the beginning of therapy with mexiletine. RESULTS: The study population comprised 34 LQT3 patients, 19 (56%) of whom were male. The median age at beginning of treatment with mexiletine was 22 years, and median QTc interval before therapy 509 ms. The median duration of oral mexiletine therapy was 36 months, at an average daily dose of 8 ± 0.5 mg/kg. Mexiletine significantly shortened QTc (by 63 ± 6 ms; p < 0.0001) and reduced the percentage of patients with arrhythmic events (from 22% to 3%; p = 0.031), the mean number of arrhythmic events per patient (from 0.43 ± 0.17 to 0.03 ± 0.03; p = 0.027), and the annual rate of arrhythmic events (from 10.3% to 0.7%; p = 0.0097). CONCLUSIONS: Besides shortening QTc interval, mexiletine caused a major reduction of life-threatening arrhythmic events in LQT3 patients, thus representing an efficacious therapeutic strategy.
Assuntos
Eletrocardiografia , Terapia Genética/métodos , Frequência Cardíaca/efeitos dos fármacos , Síndrome do QT Longo/terapia , Mexiletina/administração & dosagem , Administração Oral , Adolescente , Adulto , Criança , Feminino , Seguimentos , Humanos , Síndrome do QT Longo/genética , Síndrome do QT Longo/fisiopatologia , Masculino , Estudos Retrospectivos , Resultado do Tratamento , Bloqueadores do Canal de Sódio Disparado por Voltagem/administração & dosagem , Adulto JovemRESUMO
OBJECTIVES: This study intends to gain further insights into the natural history, the yield of familial and genetic screening, and the arrhythmogenic mechanisms in the largest cohort of short QT syndrome (SQTS) patients described so far. BACKGROUND: SQTS is a rare genetic disorder associated with life-threatening arrhythmias, and its natural history is incompletely ascertained. METHODS: Seventy-three SQTS patients (84% male; age, 26 ± 15 years; corrected QT interval, 329 ± 22 ms) were studied, and 62 were followed for 60 ± 41 months (median, 56 months). RESULTS: Cardiac arrest (CA) was the most frequent presenting symptom (40% of probands; range, <1 month to 41 years). The rate of CA was 4% in the first year of life and 1.3% per year between 20 and 40 years; the probability of a first occurrence of CA by 40 years of age was 41%. Despite the male predominance, female patients had a risk profile superimposable to that of men (p = 0.49). The yield of genetic screening was low (14%), despite familial disease being present in 44% of kindreds. A history of CA was the only predictor of recurrences at follow-up (p < 0.0000001). Two patterns of onset of ventricular fibrillation were observed and were reproducible in patients with multiple occurrences of CA. Arrhythmias occurred mainly at rest. CONCLUSIONS: SQTS is highly lethal; CA is often the first manifestation of the disease with a peak incidence in the first year of life. Survivors of CA have a high CA recurrence rate; therefore, implantation of a defibrillator is strongly recommended in this group of patients.
Assuntos
DNA/genética , Eletrocardiografia , Canais de Potássio Éter-A-Go-Go/genética , Predisposição Genética para Doença , Testes Genéticos/métodos , Mutação , Adulto , Arritmias Cardíacas/epidemiologia , Arritmias Cardíacas/genética , Arritmias Cardíacas/metabolismo , Análise Mutacional de DNA , Canais de Potássio Éter-A-Go-Go/metabolismo , Feminino , Seguimentos , Frequência do Gene , Humanos , Incidência , Itália/epidemiologia , Masculino , Taxa de Sobrevida/tendências , Fatores de Tempo , Adulto JovemAssuntos
Síndrome de Brugada/genética , Canalopatias/genética , Morte Súbita Cardíaca , Síndrome do QT Longo/genética , Taquicardia Ventricular/genética , Fibrilação Ventricular/genética , Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/genética , Arritmias Cardíacas/fisiopatologia , Síndrome de Brugada/tratamento farmacológico , Síndrome de Brugada/fisiopatologia , Canalopatias/tratamento farmacológico , Canalopatias/fisiopatologia , Feminino , Humanos , Síndrome do QT Longo/tratamento farmacológico , Síndrome do QT Longo/fisiopatologia , Masculino , Taquicardia Ventricular/tratamento farmacológico , Taquicardia Ventricular/fisiopatologia , Fibrilação Ventricular/tratamento farmacológico , Fibrilação Ventricular/fisiopatologiaRESUMO
This review article discusses the genetic bases of cardiac arrest with a specific focus on cardiac channelopathies and right ventricular cardiomyopathy. We review the appropriate use of genetic testing in those patients suspected to have inherited cardiac arrhythmias, highlighting the importance of most genotype-phenotype correlations for risk stratification. The article also presents the most recent views on diagnostic criteria and flowcharts for treatment of patients with inherited arrhythmogenic diseases.
Assuntos
Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/genética , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/genética , Eletrocardiografia , Predisposição Genética para Doença , Testes Genéticos , Genótipo , Humanos , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/genética , Prognóstico , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/genética , Disfunção Ventricular Direita/diagnóstico , Disfunção Ventricular Direita/genéticaRESUMO
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disease characterized by a structurally normal heart and high lethality beginning in early childhood. The identification of its genetic bases made possible the discovery that arrhythmias are caused by intracellular calcium dysregulation. In the 9 years since the description of the genetic substrate of the disease, we have witnessed remarkable progress in the unraveling of the molecular mechanisms underlying its arrhythmogenesis. The impact of these discoveries extends beyond the field of inherited arrhythmias and sheds new light on the arrhythmogenic mechanisms in some more prevalent diseases characterized by abnormal calcium regulation, such as heart failure. Additionally, basic research studies led to the exploration of new therapeutic strategies with potential clinical impact in the near future in reducing the still high incidence of sudden death associated with these conditions. In the current review, the authors discuss the clinical and genetic features of CPVT, highlighting pathophysiologic insights derived from experimental research and future therapeutic targets.
RESUMO
BACKGROUND: Identification of mutations in cardiac ion channel genes concurs to the diagnosis of long-QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. However, because availability of genetic screening is still limited and reimbursement policies are lacking, there is a need of evidence-based criteria to prioritize access to genetic testing for these diseases. METHODS AND RESULTS: We determined the yield of genetic testing and cost per positive genotyping in 1394 consecutive probands. Among the 546 patients referred for long-QT syndrome-genes screening, those with clinical diagnosis of long-QT syndrome had the highest yield (64%) and lowest cost (US $8418) for each positive genotyping. Among 798 individuals screened for mutation on the SCN5A gene, the highest yield was obtained in patients with type 1 Brugada syndrome ECG pattern (51 of 405; 13%) corresponding to a cost of US $21441 per positive genotyping. In conclusive Brugada syndrome patients the presence of atrioventricular block (odds ratio: 3.3, CI: 1.8 to 6.1; P=0.0001) increases the yield (23%) of genotyping and reduces its cost (US $ 11700). Among 175 patients screened on RyR2 gene, those with documented bidirectional ventricular tachycardia had the highest incidence (62%) of mutations and the lowest cost (US $5263) per positive genotyping. Genetic screening of unselected family members of sudden cardiac death victims and idiopathic ventricular fibrillation survivors is largely ineffective (yield of 9%) and costly (US $71430 per 1 positive genotyping). CONCLUSIONS: Genotyping can be performed at reasonable cost in individuals with conclusive diagnosis of long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia, and in patients with type I Brugada syndrome ECG with atrioventricular block. These patients should be given priority to access genetic testing.
Assuntos
Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/genética , Testes Genéticos , Prioridades em Saúde , Acessibilidade aos Serviços de Saúde , Canais Iônicos/genética , Programas de Rastreamento/métodos , Seleção de Pacientes , Adolescente , Adulto , Arritmias Cardíacas/economia , Bloqueio Atrioventricular/diagnóstico , Bloqueio Atrioventricular/genética , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/genética , Criança , Análise Custo-Benefício , Feminino , Predisposição Genética para Doença , Testes Genéticos/economia , Custos de Cuidados de Saúde , Prioridades em Saúde/economia , Acessibilidade aos Serviços de Saúde/economia , Humanos , Reembolso de Seguro de Saúde , Itália , Modelos Logísticos , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/genética , Masculino , Programas de Rastreamento/economia , Proteínas Musculares/genética , Mutação , Canal de Sódio Disparado por Voltagem NAV1.5 , Fenótipo , Canais de Potássio de Abertura Dependente da Tensão da Membrana/genética , Valor Preditivo dos Testes , Estudos Retrospectivos , Canal de Liberação de Cálcio do Receptor de Rianodina/genética , Canais de Sódio/genética , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/genética , Adulto JovemRESUMO
Thanks to the contribution of molecular genetics, the genetic bases, the pathogenesis and genotype-phenotype correlation of diseases such as the long QT syndrome and catecholaminergic polymorphic ventricular tachycardia have been progressively unveiled and show an extremely high degree of genetic heterogeneity. Data from clinical registries are summarized together with the recommendations provided in clinical practice guidelines for management of patients with these diseases. Furthermore the evidence supporting the importance of genetic analysis for risk stratification and therapy selections is reviewed.
Assuntos
Testes Genéticos/métodos , Síndrome do QT Longo/diagnóstico , Síndrome do QT Longo/genética , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/genética , Predisposição Genética para Doença/genética , Humanos , Síndrome do QT Longo/terapia , Taquicardia Ventricular/terapiaRESUMO
AIMS: Recent data suggest that sub-clinical structural abnormalities may be part of the Brugada syndrome (BrS) phenotype, a disease traditionally thought to occur in the structurally normal heart. In this study, we carried out detailed assessment of cardiac morphology and function using cardiac magnetic resonance imaging (CMRI). METHODS AND RESULTS: Thirty consecutive patients with BrS were compared with 30 sex- (26/4 male/female), body surface area- (+/-0.2 m(2)), and age-matched (+/-5 years) normal volunteers. CMRI exam included long- and short-axis ECG-gated breath-hold morphological T1-TSE sequences for fatty infiltration and cine-SSFP sequences for kinetic assessment. Fatty infiltration was not found in any subject. Patients with BrS compared with normal subjects showed higher incidence of mild right ventricle (RV) wall-motion abnormalities [15 (50%) vs. 5 (17%) subjects (P = 0.006) with reduced radial fractional shortening in more than two segments], reduction of outflow tract ejection fraction (49 +/- 11% vs. 55 +/- 10%; P = 0.032), enlargement of the inflow tract diameter (46 +/- 4 vs. 41 +/- 5 mm, P < 0.001 in short-axis; 46 +/- 4 vs. 42 +/- 5 mm, P = 0.001 in four-chamber long-axis view) and area (22 +/- 2 vs. 20 +/- 3 cm(2); P = 0.050), and of global RV end-systolic volume (34 +/- 10 vs. 30 +/- 6 mL/m(2); P = 0.031) but comparable outflow tract dimensions, global RV end-diastolic volume, left ventricle parameters, and atria areas. CONCLUSION: CMRI detects a high prevalence of mild structural changes of the RV, and suggests further pathophysiological complexity in BrS. Prospective studies to assess the long-term evolution of such abnormalities are warranted.
Assuntos
Síndrome de Brugada/patologia , Adolescente , Adulto , Idoso , Síndrome de Brugada/fisiopatologia , Estudos de Casos e Controles , Morte Súbita Cardíaca/patologia , Feminino , Ventrículos do Coração/patologia , Humanos , Angiografia por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Contração Miocárdica/fisiologia , Volume Sistólico/fisiologia , Adulto JovemRESUMO
BACKGROUND: Effective automatic mode switching (AMS) algorithms capable of detecting a range of supraventricular tachyarrhythmias is important given evidence of atrial fibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT) post-implantation of pacemakers. OBJECTIVES: The aim of the study was to assess the efficacy, defined as ability to detect a specific atrial rate and activate AMS, of five different AMS mechanisms during simulation of AF, AFL, and AT. MATERIALS AND METHODS: A total of 48 subjects (35 men, 13 women; mean age: 69 +/- 8 years) implanted with DDDR pacemakers utilizing five different AMS mechanisms (mean atrial rate, rate cut-off, complex 'fallback' algorithm, retriggerable atrial refractory period, and physiological band 'beat-to-beat') were tested using an external electronic device that simulated the occurrence of supraventricular tachyarrhythmias. AF, AFL, and AT were simulated by delivering low voltage pulse trains at 350, 250 and 160 beats/min, respectively. RESULTS: Mean efficacy for all AMS mechanisms was 81% [range: 57% to 100%] at 350 beats/min, 81% [range: 57-100%] at 250 beats/min, and 79% [range: 57-100%] at 160 beats/min. The AMS mechanisms that yielded 100% efficacy were the rate cut-off and physiological band 'beat-to-beat.' CONCLUSION: Not all AMS algorithms are equally efficacious at detecting atrial arrhythmias and subsequently activating AMS. Our results suggest that the most efficacious AMS algorithms are those that use rate cut-off and physiological band 'beat-to-beat' to detect supraventricular tachyarrhythmias.
Assuntos
Algoritmos , Estimulação Cardíaca Artificial/métodos , Marca-Passo Artificial , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/prevenção & controle , Terapia Assistida por Computador/métodos , Idoso , Desenho de Equipamento , Análise de Falha de Equipamento , Feminino , Humanos , Masculino , Resultado do TratamentoRESUMO
BACKGROUND: Transthoracic electrical cardioversion represents the most effective therapy in converting atrial fibrillation (AF) to sinus rhythm. External cardioverter-defibrillators discharge a current with monophasic and most recently biphasic waveforms. Lately, many articles support the superiority of the biphasic waveform over the monophasic one. Moreover, we have the opportunity to use different biphasic waveforms. The aim of this study was to compare the efficacy (success rate and energy delivered) of a monophasic wave and two different biphasic waves, in patients with persistent AF undergoing external electrical cardioversion. The monophasic wave was delivered by a Zoll M series NM PDMA-9, while the so-called "rectilinear" biphasic waveform was used by a Zoll M series PDM-7S and the biphasic truncated exponential wave by a Laerdal Heartstart 4000. METHODS: Sixty-four patients with clinical indications to undergo external electrical cardioversion were randomized into three groups. All the groups were homogeneous for almost all characteristics, particularly atrial dimensions, body surface area, and duration of AF and therapy. Eighteen patients underwent external cardioversion with monophasic waveform (group 1), 22 patients were treated with rectilinear biphasic waveform (group II), and 24 patients with biphasic truncated waveform (group III). A cardioversion protocol, providing up to 5 shocks, with incremental energy levels was used. A blood sample was obtained 6 hours later to evaluate myocardial damage due to shock therapy for each patient. RESULTS: Both biphasic devices demonstrated to be more effective than the monophasic one (group I 78%, group II 95%, group III 100%). Moreover, none of them caused any significant myocardial damage, evaluated in terms of cardiac enzyme release. Nonetheless, the biphasic truncated exponential wave demonstrated an efficiency of 10 0% compared to 95 % of the rectilinear one and 78% of the monophasic one, using less energy/patient (873 +/- 101 J group I, 390 +/- 48 J group II, and 280 +/- 42 J group III), at almost the same shock attempts. CONCLUSIONS: Biphasic truncated exponential wave seems to be more effective at a lower energy level.
Assuntos
Fibrilação Atrial/terapia , Cardioversão Elétrica/métodos , Eletrofisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , TóraxRESUMO
BACKGROUND: In order to correct the activation, contraction, and relaxation asynchronism, multisite biventricular stimulation has been proposed as a non-pharmacological alternative for the treatment of patients with congestive heart failure (CHF) NYHA class II-III-IV, resistant to maximal drug therapy and with a QRS duration > 120 ms. Fourier analysis appears a feasible technique for the quantitative and non-invasive evaluation of the inter- and intraventricular conduction delays. The aim of our study was to evaluate the usefulness of Fourier analysis when estimating the electromechanical resynchronization in CHF biventricular paced patients and to follow up these patients. METHODS: Forty-five male patients (mean age 64 +/- 5 years) with severe drug-refractory CHF, were submitted to radionuclide ventriculography 14 +/- 7 days, 24 and 36 months after the implantation of a biventricular pacemaker, in order to assess left ventricular ejection fraction using Fourier analysis of the right and left ventricular phase images. Each patient was examined during spontaneous sinus rhythm, P-synchronous right ventricle and P-synchronous biventricular pacing. RESULTS: Fourteen days after biventricular pacemaker implantation, QRS duration decreased from 170 +/- 25 to 147 +/- 25 ms (p < 0.01), left ventricular ejection fraction increased from 24 +/- 6 to 31 +/- 9% (p < 0.005), while standard deviation of the left ventricular phase decreased from 53 +/- 6 to 35 +/- 9 degrees (p < 0.0005). Similar results were obtained at 24 and 36 months. CONCLUSIONS: Biventricular pacing appears to be associated with shortening of QRS duration and an improvement in NYHA class and left ventricular ejection fraction in CHF patients with inter- and intraventricular conduction delays as assessed at Fourier analysis radionuclide ventriculography.